are less potent. In refractory cardiac arrest the improved survival rates by using vasopressin with epinephrine fits with a recent pig based study and may be due to a synergistic effect of the two drugs, especially in prolonged ischaemia.
This study did not demonstrate any clinically significant difference in neurological outcome but the numbers surviving were small (especially for those who had additionally received epinephrine, where 50% had severe cerebral disability or were comatose compared to only 20% that received epinephrine alone). There may well have been more survivors using vasopressin, but what level of cerebral functioning and quality of life will they have? I feel that larger groups are needed before we can say for definite that cerebral outcome is not affected. The implications for the patient, and indeed the increased cost of care if there was poor cerebral outcome, are substantial.
Another issue that would need to be resolved if vasopressin is to be introduced into CPR protocols is that prefilled vasopressin syringes are not currently available in the UK and the preparation that is available needs to be stored at 2-8 oC and costs £35 for 40 IU. This would prevent it being included in many emergency drug boxes across the hospital unless refrigeration was available. There is a preparation available in America that can be stored at room temperature that may in the future be licensed in the UK.
Overall, whilst vasopressin may well have an important role to play in cardiopulmonary resuscitation, I feel that we need to ensure that this isn't at the cost of significant impairment of cerebral performance. s Background The use of heparin to prevent clotting of the extracorporeal circuit during continuous renal replacement therapy is associated with an increased risk of haemorrhage 1 . Regional anticoagulation of the circuit with citrate may reduce this risk [2] [3] [4] . Citrate, infused proximal to the haemofilter, chelates ionised calcium and prevents circuit clotting. Systemic anticoagulation is prevented by restoring serum ionised calcium by intravenous infusion. Potential adverse effects include systemic hypocalcaemia, hypernatraemia (citrate as the trisodium salt) and metabolic alkalosis (nonfiltered citrate is metabolised to bicarbonate).
The aim of this study was to compare the safety and efficacy of regional citrate anticoagulation with standard heparin anticoagulation.
Abstract
This study was a single-centre, prospective, non-blinded, randomised crossover trial of citrate vs. heparin in continuous venovenous haemofiltration (CVVH). The study group comprised vasopressor dependent, mechanically ventilated patients who developed acute renal failure and required continuous renal replacement therapy. CVVH was chosen in preference to daily dialysis in these patients because of haemodynamic instability. Exclusion criteria included those with a high risk of bleeding (recent surgery, severe coagulopathy and liver cirrhosis).
Size of study
Forty-seven patients received CVVH over the one year study period, of whom twenty patients were enrolled in the trial. The remainder were excluded on the above criteria.
Intervention
On commencing the first run of CVVH, patients were randomised to receive either heparin or citrate. Subsequent filters were run with the alternate protocol. Crossover continued up to a maximum of four circuits for each patient. Heparin was administered to achieve an activated partial thromboplastin time of 60-80s. The citrate group followed a sliding scale of trisodium citrate and calcium chloride infusions to maintain circuit ionised calcium < 0.3mmol/l and serum ionised calcium within the normal range.
Outcomes
The primary end point was time to failure of the haemofilter. Secondary end points were transfusion requirements, incidence of major bleeding and metabolic complications.
Results
Median circuit lifetime for heparin was 40 hours (interquartile range (IQR) 17h-48h), and for citrate 70 hours (44h-140h), p=0.0007. Median number of red cell units transfused was 1.0 unit/day (IQR 0-2.0) in the heparin group vs. 0.2 unit/day (0-0.4) in the citrate group, p=0.0008. Major bleeding occurred in one patient on heparin and metabolic complications occurred in two patients on citrate.
Are the results of the study valid?
Primary Guides
The randomisation process assigning patients to treatment groups is not described, but this is less important in a crossover study. Twenty patients utilised 49 filters, with up to four filters studied per patient. However, it is unclear whether all patients were in fact crossed from one arm of the study to the other. All circuits appear to have been analysed in the groups to which they were randomised.
Secondary Guides
The trial was not blinded. Although complete blinding would have been impractical, there emerges the potential to bias the results of secondary outcomes where numbers are small. Groups were treated equally, apart from the treatment intervention.
Subgroup analysis
The authors originally defined circuit failure as time to spontaneous failure or elective discontinuation. There were six elective discontinuations in the citrate group and one in the heparin group. A subgroup comprising only spontaneous failures was later analysed. The rationale for this subgroup analysis is reasonable and the results appear to make biological sense. The median circuit lifetime is statistically different between groups and a difference of this magnitude would also be relevant in clinical practice. The study findings were hypothesised at the start of the study. Independent studies on the subject quote widely discrepant times for circuit lifetime, presumably relating to extensive variations in the protocols used for citrate anticoagulation [2] [3] [4] .
Are the valid results of this trial important?
Primary outcome
The risk reduction was calculated at time points 50 hours and 100 hours from the Kaplan-Meier curve of time to spontaneous circuit failure.
Rate of spontaneous circuit failure with heparin at 50h = 0.77
Rate of spontaneous circuit failure with citrate at 50h = 0.30
Relative risk reduction = 0.61
Absolute risk reduction = 0.47 (95%CI 0.21-0.74) NNT = 3 (95%CI 2-5) Hence 3 circuits need to be anticoagulated with citrate rather than heparin to prevent one spontaneous circuit failure at 50h.
Results are similar at 100h: ARR = 0.45 (95%CI 0.22-0.69) NNT = 3 (95% CI 2-5).
Secondary outcomes
Transfusion requirements appear significantly lower in the citrate group (1.0 vs. 0.2 units per day). Part of this difference is attributed to a lower incidence of circuit clotting, but several other factors need to be considered. Transfusion therapy may have been initiated at a time remote from the actual fall in haemoglobin when patients could already have crossed to the other arm of the trial. Together with a lack of blinding, this provides a potential source of bias.
The study patients are similar to many of our patients requiring CVVH in the intensive care unit. The end points of time to circuit failure and transfusion requirements are also relevant to our practice. However, since patients with liver cirrhosis and those at a high risk of bleeding were excluded from the study, several issues relevant to our patient population remain unresolved.
